A newly published study in The New England Journal of Medicine shows that in premenopausal women with early breast cancer administering Zometa(R) (zoledronic acid) along with post-surgery hormone therapy provided a reduction in risk of recurrence or death that was 36% beyond that achieved with hormone therapy alone(1).
More...